KR20180081812A - 허혈성 뇌졸중 치료용 조성물 및 방법 - Google Patents

허혈성 뇌졸중 치료용 조성물 및 방법 Download PDF

Info

Publication number
KR20180081812A
KR20180081812A KR1020187017549A KR20187017549A KR20180081812A KR 20180081812 A KR20180081812 A KR 20180081812A KR 1020187017549 A KR1020187017549 A KR 1020187017549A KR 20187017549 A KR20187017549 A KR 20187017549A KR 20180081812 A KR20180081812 A KR 20180081812A
Authority
KR
South Korea
Prior art keywords
compound
formula
cromolyn
stroke
brain
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
KR1020187017549A
Other languages
English (en)
Korean (ko)
Inventor
데이빗 엘마레
Original Assignee
아즈테라피즈 인코포레이티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 아즈테라피즈 인코포레이티드 filed Critical 아즈테라피즈 인코포레이티드
Publication of KR20180081812A publication Critical patent/KR20180081812A/ko
Withdrawn legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pulmonology (AREA)
  • Otolaryngology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
KR1020187017549A 2015-11-23 2016-11-23 허혈성 뇌졸중 치료용 조성물 및 방법 Withdrawn KR20180081812A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562258882P 2015-11-23 2015-11-23
US62/258,882 2015-11-23
PCT/US2016/063462 WO2017091644A1 (en) 2015-11-23 2016-11-23 Compositions and methods for treating ischemic stroke

Publications (1)

Publication Number Publication Date
KR20180081812A true KR20180081812A (ko) 2018-07-17

Family

ID=58764360

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020187017549A Withdrawn KR20180081812A (ko) 2015-11-23 2016-11-23 허혈성 뇌졸중 치료용 조성물 및 방법

Country Status (9)

Country Link
US (2) US20180344682A1 (enExample)
EP (1) EP3380095B1 (enExample)
JP (1) JP2018538273A (enExample)
KR (1) KR20180081812A (enExample)
CN (1) CN108472275A (enExample)
AU (1) AU2016359674A1 (enExample)
CA (1) CA3005909A1 (enExample)
MX (1) MX390748B (enExample)
WO (1) WO2017091644A1 (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9925282B2 (en) 2009-01-29 2018-03-27 The General Hospital Corporation Cromolyn derivatives and related methods of imaging and treatment
CN109846862A (zh) 2012-10-25 2019-06-07 通用医疗公司 治疗阿尔茨海默病及相关疾病的组合疗法
US10525005B2 (en) 2013-05-23 2020-01-07 The General Hospital Corporation Cromolyn compositions and methods thereof
EP3060205A4 (en) 2013-10-22 2017-06-28 The General Hospital Corporation Cromolyn derivatives and related methods of imaging and treatment
WO2018045217A1 (en) * 2016-08-31 2018-03-08 The General Hospital Corporation Macrophages/microglia in neuro-inflammation associated with neurodegenerative diseases
EP3654946A4 (en) 2017-07-20 2021-04-21 AZTherapies, Inc. CROMOLYNE SODIUM AND IBUPROFEN POWDER FORMULATIONS
JP2021505658A (ja) * 2017-12-04 2021-02-18 ザ ジェネラル ホスピタル コーポレイション クロモリン組成物及びその方法
AU2019251191A1 (en) * 2018-04-09 2020-10-29 The General Hospital Corporation Combination therapies for the treatment of amyotropic lateral sclerosis and related disorders
CN113038944A (zh) 2018-07-02 2021-06-25 通用医疗公司 色甘酸钠和α-乳糖的粉末化制剂
MX2021006869A (es) 2018-12-10 2021-07-02 Massachusetts Gen Hospital Esteres de cromolin y usos de los mismos.
WO2021207060A1 (en) 2020-04-06 2021-10-14 The General Hospital Corporation Methods of treatment of coronavirus-induced inflammation conditions

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004071531A1 (en) 2003-02-13 2004-08-26 Licentia Oy Use of a mast cell activation or degranulation blocking agent in the manufacture of a medicament for the treatment of cerebral ischemia
CN101035541B (zh) * 2004-08-30 2012-05-30 柳署弘 溶解的udca在局灶缺血模型中的神经保护作用
CN102341391B (zh) 2009-01-29 2015-08-19 通用医疗公司 色甘酸衍生物以及制备成像和治疗的药物中的应用
US9925282B2 (en) * 2009-01-29 2018-03-27 The General Hospital Corporation Cromolyn derivatives and related methods of imaging and treatment
KR101579771B1 (ko) * 2009-03-05 2015-12-28 애브비 인코포레이티드 Ｉｌ-17 결합 단백질
TW201036972A (en) * 2009-03-11 2010-10-16 Plexxikon Inc Compounds and uses thereof
CN109846862A (zh) * 2012-10-25 2019-06-07 通用医疗公司 治疗阿尔茨海默病及相关疾病的组合疗法
MX381503B (es) * 2013-05-23 2025-03-12 Aztherapies Inc Métodos para la liberación de cromolina.
EP3060205A4 (en) * 2013-10-22 2017-06-28 The General Hospital Corporation Cromolyn derivatives and related methods of imaging and treatment
AU2015213678C1 (en) * 2014-02-10 2019-03-21 Respivant Sciences Gmbh Mast cell stabilizers treatment for systemic disorders
WO2018045217A1 (en) * 2016-08-31 2018-03-08 The General Hospital Corporation Macrophages/microglia in neuro-inflammation associated with neurodegenerative diseases

Also Published As

Publication number Publication date
EP3380095A4 (en) 2019-10-23
WO2017091644A1 (en) 2017-06-01
EP3380095A1 (en) 2018-10-03
US20180344682A1 (en) 2018-12-06
CN108472275A (zh) 2018-08-31
MX2018006390A (es) 2019-02-14
CA3005909A1 (en) 2017-06-01
MX390748B (es) 2025-03-21
AU2016359674A1 (en) 2018-06-14
EP3380095B1 (en) 2022-01-05
US20220125753A1 (en) 2022-04-28
JP2018538273A (ja) 2018-12-27

Similar Documents

Publication Publication Date Title
US20220125753A1 (en) Compositions and methods for treating ischemic stroke
TW201505634A (zh) 藥物戒斷之無毒治療方法
WO2001060407A2 (de) Neue kombination nichtsedierender antihistaminika mit substanzen, die die leukotrienwirkung beeinflussen, zur behandlung der rhinitis/konjunktivitis
CA3025702A1 (en) Stable cannabinoid formulations
CN117377476B (zh) 治疗与化学疗法诱发的周围神经病变相关的疼痛
KR20180051561A (ko) 특정 환자 집단에서 신경퇴행성 장애를 치료하는 방법
JP2020510675A (ja) ミトコンドリア起源のｒｏｓの産生の特異的阻害剤を使用した、薬物誘発ｑｔ間隔延長に関連するリスクの予防
MX2011006353A (es) Derivados de 1-amino-alquilciclohexano para el tratamiento de enfermedades mediadas por mastocitos.
US20100055176A1 (en) Method of Treating Fibromyalgia or Associated Functional Symptoms of Fibromyalgia
CN1235545A (zh) 含有氯雷他定和减充血剂的用于治疗哮喘的组合物
US20060276495A1 (en) Treatment methods of nasal congestion and nasal obstruction
ES2534560T3 (es) Acetato de eslicarbazepina y su uso
EP2056826B1 (en) Compositions and methods for increasing blood platelet levels in humans
KR20170012480A (ko) 당뇨병을 치료하기 위한 카페스톨
HK1255498A1 (en) Liposomal mitigation of drug-induced long qt syndrome and potassium delayed-rectifier current
JPH0251885B2 (enExample)
KR20090024248A (ko) Ｃｘｃｒ2의 선택적 길항제 또는 ｃｘｃｒ1과 ｃｘｃｒ2 둘다의 선택적 길항제의 약제학적 제형 및 조성물, 및 염증성 질환을 치료하기 위한 이의 사용방법
Hartnett et al. Comparison of oral theophylline and salbutamol by inhalation in asthmatic patients
EP0813878A1 (en) Lacrimation accelerating agent containing a serotonin ligand, especially aminoalkoxybibenzyl compounds
US20040009971A1 (en) Use of alprazolam in treatment of disorders of the central nervous system
US20120028976A1 (en) Pharmacokinetically-based dosing regiments of a thrombin receptor antagonist
KR20240113389A (ko) 퇴행성 골관절염의 예방 또는 치료용 약학적 조성물
Cutler et al. Pharmacokinetics and pharmacodynamics of avitriptan in patients with migraine after oral dosing
CA2450583A1 (en) Antihistamines for the treatment of nasal congestion and nasal obstruction
Yeung et al. PII‐66: Pharmacokinetics and hemodynamic effects of diltiazem in rats following single and repeated subcutaneous injection in vivo

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

R18-X000 Changes to party contact information recorded

St.27 status event code: A-3-3-R10-R18-oth-X000

A201 Request for examination
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

PC1202 Submission of document of withdrawal before decision of registration

St.27 status event code: N-1-6-B10-B11-nap-PC1202

P22-X000 Classification modified

St.27 status event code: A-2-2-P10-P22-nap-X000